Bayesian survival analysis reveals comprehensive efficacy profile and mechanism of action for Sanofi-Pasteur’s CYD-TDV dengue vaccine, whereby vaccination acts as a silent, disease-free infection enhancing disease risk in seronegatives, but giving greater immunity in seropositives than two natural infections.

In large vaccine trials conducted in dengue-endemic Asia and Latin America, the CYD-TDV tetravalent dengue vaccine shows limited variation in intra-serotype efficacy in the target population for vaccination (>9 years).

Using single-cell CITE-seq to implicate monocytes as the cellular origin of a protective HIV vaccine gene signature.

Natural transmission experiments should be prioritised over risky and expensive field trials, in order to establish the impact of cattle vaccination on the transmission of bovine Tuberculosis.

Strategies to enhance Tfh cells for HIV-vaccine antibody persistence and protection is pivotal for vaccine success.

ePAC, a novel cancer vaccine utilizing a mammalian-derived virus-like particle to co-deliver neoantigens and CpG-ODN, demonstrates strong antitumor efficacy in mouse models.

Antibody responses to individual and optimal combinations of P. vivax recombinant proteins in naturally-exposed populations help to identify correlates of protective immunity, and establish a clear path to testing a multicomponent P. vivax vaccine.

Influenza vaccination in humans stimulates novel B cell evolution that is detectable in germinal centers, but not the peripheral blood.

Circulating T follicular helper cells appear to be a promising biomarker candidate for monitoring vaccine efficacy in malaria vaccine trials.

An attenuated Herpes simplex type 2 virus deleted in glycoprotein D can be used as an effective vaccine to provide robust transferable humoral immunity and complete protection in murine intravaginal and skin infection models.